Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
- Bill Number
- S. 2531
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- Last Updated
- 2026-05-14T11:03:27Z
AI-Generated Summary
Summary of S. 2531: Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
Purpose
This legislation aims to improve health outcomes for individuals with uterine fibroids by authorizing the Secretary of Health and Human Services to fund research and state-level programs focused on earlier detection and intervention.
Key Provisions
- Research Mandate: The Secretary must conduct or support studies on early detection and intervention for uterine fibroids, then develop evidence-based strategies for use in health care settings.
- Grant Program for States: The Secretary may award grants to states to run programs that boost early detection and intervention, including public awareness campaigns. Funds can cover screening procedures (such as advanced imaging), patient navigation services, strategy implementation, and access to care settings.
- Additional Research Grants: Grants are available for studies on disparities in pain control during fibroid surgery and conditions like Asherman's Syndrome or intrauterine adhesions.
- Reporting Requirements: The Secretary must submit reports to Congress every two years summarizing grant activities, results, and related research findings, with public availability on the Department of Health and Human Services website.
Significant Changes to Existing Law
The bill introduces new grant authorities and research requirements under the Department of Health and Human Services. It does not amend or repeal prior statutes but establishes fresh mechanisms for funding and coordination.
Potential Impacts
- Government Agencies: The Department of Health and Human Services gains responsibilities for research, strategy development, and grant oversight, while states would manage and implement funded programs.
- Citizens: Individuals affected by uterine fibroids, particularly those in underserved groups, may gain better access to screening, education, and care, potentially leading to earlier treatment and reduced health complications.
- International Relations: No direct effects identified.
Main Stakeholders Affected
- Women and individuals diagnosed with or at risk for uterine fibroids.
- State health departments as grant recipients.
- The Department of Health and Human Services as the administering agency.
- Health care providers and researchers involved in gynecological care.
- Advocacy groups focused on women's health.
Notable Legal, Constitutional, or Political Implications
The bill operates within existing federal public health authorities and raises no apparent constitutional concerns. It emphasizes addressing health disparities in pain management but contains no provisions that alter legal rights or create new regulatory frameworks.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Alsobrooks, Angela D. [D-MD]
Cosponsors (3)
Sen. Lummis, Cynthia M. [R-WY], Sen. Marshall, Roger [R-KS], Sen. Hickenlooper, John W. [D-CO]
Recent Actions
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- 2025-07-30: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-07-30: Introduced in Senate
Bill Versions
- Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 — issued 2025-07-30 — PDF (4 pages)